Journal
CANCER
Volume 115, Issue 22, Pages 5202-5209Publisher
WILEY
DOI: 10.1002/cncr.24575
Keywords
MDS; deletion 5q; lenalidomide
Categories
Funding
- National Institutes of Health National Cancer Institute [1P50CA100632-04, PO1CA108631]
Ask authors/readers for more resources
BACKGROUND: To define the prognosis in myelodysplastic syndrome (MDS) and deletion 5q with or without other cytogenetic abnormalities. METHODS: Patients with MDS (<20% blasts) and evaluable cytogenetic studies (1966-present) were reviewed. Outcome of patients with deletion 5q or with loss of chromosome 5 (monosomy 5) was analyzed. RESULTS: Of 2743 patients analyzed, 287 (10%) had deletion 5q and 216 (8%) had monosomy 5 abnormalities. The median survival was 9 months with deletion 5q, 6 months with monosomy S, and 17 months without a chromosome 5 abnormality. Considering patients with deletion 5q, the median survival was 33 months with deletion 5q alone, 17 months with deletion 5q and I additional abnormality, but only 6 months to 12 months with deletion 5q and >= 2 abnormalities or chromosome 7 abnormality. Only 93 patients (3.4% of total) had lower risk MDS (international prognostic scoring system low or intermediate 1) and deletion 5q; their median survival was 29 months (2-year survival 60%), and ranged from 13-41 months depending on the presence or absence of additional chromosomal abnormalities. Among 198 patients with MDS with deletion 5q and <10% blasts (a subset now often offered lenalidomide), the median survival was 12 months. Monosomy 5 was significantly more frequently associated with advanced MDS and with other chromosomal abnormalities. CONCLUSIONS: This study provided baseline expectations of outcome in different MDS subsets and deletion 5q. Cancer 2009;115:5202-09. (C) 2009 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available